Evidence map›Paper›PMID 38190801›Full record

ArticleJournal of the National Comprehensive Cancer Network : JNCCN2024

Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events.

Sarah E Fayle, Nicolas L Palaskas, Bilal A Siddiqui, Jennifer L McQuade, Jamie S Lin, Sumit K Subudhi, Anisha B Patel, Robert R Jenq, Amishi Y Shah, Amy R Spelman and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Comprehensive Cancer Network : JNCCN, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Sarah E FayleDivision of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Nicolas L PalaskasDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Bilal A SiddiquiDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jennifer L McQuadeDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jamie S LinSection of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sumit K SubudhiDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Anisha B PatelDepartment of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Robert R JenqDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Amishi Y ShahDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Amy R SpelmanDivision of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mianen SunDivision of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Bettina H MarbleDepartment of Cancer Medicine Administration, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yinghong WangDepartment of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Project 3: Enhanced Sensitivity of Tumors to Proton Beam Therapy: Mechanisms and Biomarkers.P01CA261669 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI GROSSHANS, DAVID R · 2021 to 2025
$14.0M
The role of ARF6 in the progression of diabetic kidney diseaseK08DK119466 · NIDDK · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIN, JAMIE · 2019 to 2023
$826k
NCI NIH HHS P01 CA261669NCI NIH HHS P30 CA016672NIDDK NIH HHS K08 DK119466
6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for many cancer types. The clinical use of ICIs is increasing rapidly, including in combinations associated with increased risk of toxicities, termed "immune-related adverse events" (irAEs). Therefore, MD Anderson Cancer Center (MDACC) in Houston, Texas has proactively responded by developing a priority endeavor known as the Immuno-Oncology Toxicity (IOTOX) initiative. This strategic initiative aims to facilitate the seamless integration of key domains: (1) standardized clinical practice and innovative decision toolsets; (2) patient and provider education; and (3) a comprehensive clinical and translational research platform. The ultimate goal of this initiative is to develop and disseminate clinical best practices and biologic insights into irAEs to improve outcomes of patients with irAEs at MDACC and in the wider oncology community.

Indexed as

Immune Checkpoint InhibitorsNeoplasmsDrug-Related Side Effects and Adverse ReactionsHumansImmunotherapyTexasImmune Checkpoint Inhibitors

Identifiers

PMID38190801
PMCPMC12381944
OpenAlexW4390674497

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.